US20150080318A1 - Compositions for the Treatment or Prophylaxis of Viral Infections - Google Patents
Compositions for the Treatment or Prophylaxis of Viral Infections Download PDFInfo
- Publication number
- US20150080318A1 US20150080318A1 US14/547,988 US201414547988A US2015080318A1 US 20150080318 A1 US20150080318 A1 US 20150080318A1 US 201414547988 A US201414547988 A US 201414547988A US 2015080318 A1 US2015080318 A1 US 2015080318A1
- Authority
- US
- United States
- Prior art keywords
- compound
- val
- fmoc
- pro
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title description 12
- 238000011282 treatment Methods 0.000 title description 12
- 208000036142 Viral infection Diseases 0.000 title description 6
- 238000011321 prophylaxis Methods 0.000 title description 6
- 230000009385 viral infection Effects 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 90
- 150000001413 amino acids Chemical class 0.000 claims abstract description 28
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 21
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 21
- 229940024606 amino acid Drugs 0.000 claims abstract description 20
- 235000001014 amino acid Nutrition 0.000 claims abstract description 20
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 19
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004474 valine Substances 0.000 claims abstract description 12
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 11
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 11
- 230000007935 neutral effect Effects 0.000 claims abstract description 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 8
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 claims abstract description 8
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 claims abstract description 8
- 235000004279 alanine Nutrition 0.000 claims abstract description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims abstract description 6
- 239000004471 Glycine Substances 0.000 claims abstract description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229960000310 isoleucine Drugs 0.000 claims abstract description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 5
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000004473 Threonine Substances 0.000 claims abstract description 5
- FJLFXMJCHNQICR-RXMQYKEDSA-N (2r)-1,2-dihydroxypyrrolidine-2-carboxylic acid Chemical compound ON1CCC[C@@]1(O)C(O)=O FJLFXMJCHNQICR-RXMQYKEDSA-N 0.000 claims abstract description 4
- IADUEWIQBXOCDZ-VKHMYHEASA-N (S)-azetidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 claims abstract description 4
- OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 claims abstract description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims abstract description 4
- RLZXKARDPOFVNB-UHFFFAOYSA-N aziridine-1-carboxylic acid Chemical compound OC(=O)N1CC1 RLZXKARDPOFVNB-UHFFFAOYSA-N 0.000 claims abstract description 4
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960002591 hydroxyproline Drugs 0.000 claims abstract description 4
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims abstract description 4
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 230000001268 conjugating effect Effects 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract description 5
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 38
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 37
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 24
- 229940125904 compound 1 Drugs 0.000 description 23
- -1 4-(2-benzoxazolyl) phenyl Chemical group 0.000 description 21
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 17
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 16
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 229960004295 valine Drugs 0.000 description 16
- 229940125898 compound 5 Drugs 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 13
- 0 [10*]C1=C([Ar])CC2=NC(=C)N(C(C)CC(C)C[W]=O)C([11*])=C21 Chemical compound [10*]C1=C([Ar])CC2=NC(=C)N(C(C)CC(C)C[W]=O)C([11*])=C21 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 229940002612 prodrug Drugs 0.000 description 12
- 239000000651 prodrug Substances 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000000840 anti-viral effect Effects 0.000 description 8
- 238000000921 elemental analysis Methods 0.000 description 8
- 239000006260 foam Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 238000010511 deprotection reaction Methods 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 7
- 229960003767 alanine Drugs 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000012888 bovine serum Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940125773 compound 10 Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000005886 esterification reaction Methods 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229960003136 leucine Drugs 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 108010016626 Dipeptides Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229940127073 nucleoside analogue Drugs 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- PNFSGKNIZOXLKU-VXKWHMMOSA-N (2s)-1-[(2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoyl]pyrrolidine-2-carboxylic acid Chemical compound O=C([C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(C)C)N1CCC[C@H]1C(O)=O PNFSGKNIZOXLKU-VXKWHMMOSA-N 0.000 description 3
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 3
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 3
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 3
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QAZQPKYFIJBOQF-UHFFFAOYSA-N CCCCCC1=CC=C(C2=CC3=CN(C4CC(O)C(COC(=O)C(NC(=O)C5CCCN5C(=O)C(N)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(C2=CC3=CN(C4CC(OC(=O)C(NC(=O)C5CCCN5C(=O)C(N)C(C)C)C(C)C)C(CO)O4)C(=O)N=C3O2)C=C1 Chemical compound CCCCCC1=CC=C(C2=CC3=CN(C4CC(O)C(COC(=O)C(NC(=O)C5CCCN5C(=O)C(N)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(C2=CC3=CN(C4CC(OC(=O)C(NC(=O)C5CCCN5C(=O)C(N)C(C)C)C(C)C)C(CO)O4)C(=O)N=C3O2)C=C1 QAZQPKYFIJBOQF-UHFFFAOYSA-N 0.000 description 2
- JPEDNDOIDKZKSZ-UHFFFAOYSA-N CCCCCC1=CC=C(C2=CC3=CN(C4CC(OC(=O)C(NC(=O)C5CCCN5C(=O)C(N)C(C)C)C(C)C)C(COC(=O)C(NC(=O)C5CCCN5C(=O)C(N)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1 Chemical compound CCCCCC1=CC=C(C2=CC3=CN(C4CC(OC(=O)C(NC(=O)C5CCCN5C(=O)C(N)C(C)C)C(C)C)C(COC(=O)C(NC(=O)C5CCCN5C(=O)C(N)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1 JPEDNDOIDKZKSZ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GIAZPLMMQOERPN-YUMQZZPRSA-N Val-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O GIAZPLMMQOERPN-YUMQZZPRSA-N 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- AJZDHLHTTJRNQJ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(tetrazol-1-yl)ethyl]benzamide Chemical compound N1(N=NN=C1)CCNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O AJZDHLHTTJRNQJ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WVRUNFYJIHNFKD-WDSKDSINSA-N Arg-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N WVRUNFYJIHNFKD-WDSKDSINSA-N 0.000 description 1
- LQJAALCCPOTJGB-YUMQZZPRSA-N Arg-Pro Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O LQJAALCCPOTJGB-YUMQZZPRSA-N 0.000 description 1
- DVUFTQLHHHJEMK-IMJSIDKUSA-N Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O DVUFTQLHHHJEMK-IMJSIDKUSA-N 0.000 description 1
- UKGGPJNBONZZCM-WDSKDSINSA-N Asp-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O UKGGPJNBONZZCM-WDSKDSINSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- MLLIWVNKHRXMFD-IZNLTOPRSA-N CC1=C(C)C(C)CC1C.[3H]C1C(C)CC(C)C1(C)C Chemical compound CC1=C(C)C(C)CC1C.[3H]C1C(C)CC(C)C1(C)C MLLIWVNKHRXMFD-IZNLTOPRSA-N 0.000 description 1
- HUVVJJCYADRRQW-UHFFFAOYSA-N CC1=CC=C(/C2=C/C3=CN(C4CC(O)C(CO)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN(C4CC(O)C(CO)O4)C(=O)N=C3O2)C=C1 Chemical compound CC1=CC=C(/C2=C/C3=CN(C4CC(O)C(CO)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN(C4CC(O)C(CO)O4)C(=O)N=C3O2)C=C1 HUVVJJCYADRRQW-UHFFFAOYSA-N 0.000 description 1
- OQNCRBYRYYCKKN-FFZLLISXSA-N CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(O)[C@@H](CO)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(O)[C@@H](COC(=O)C(N)C(C)C)O4)C(=O)N=C3O2)C=C1 Chemical compound CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(O)[C@@H](CO)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(O)[C@@H](COC(=O)C(N)C(C)C)O4)C(=O)N=C3O2)C=C1 OQNCRBYRYYCKKN-FFZLLISXSA-N 0.000 description 1
- OUWHNPRUPSQQBR-AXPFYHDFSA-N CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(O)[C@@H](CO)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)[C@@H](COC(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)O4)C(=O)N=C3O2)C=C1 Chemical compound CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(O)[C@@H](CO)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)[C@@H](COC(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)O4)C(=O)N=C3O2)C=C1 OUWHNPRUPSQQBR-AXPFYHDFSA-N 0.000 description 1
- PQNIPBYZCVJZCS-YEMACFDESA-N CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(O)[C@@H](CO)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O4)C(=O)N=C3O2)C=C1 Chemical compound CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(O)[C@@H](CO)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O4)C(=O)N=C3O2)C=C1 PQNIPBYZCVJZCS-YEMACFDESA-N 0.000 description 1
- NRIHVLQKPRYWEH-XORYCLPQSA-N CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(O)[C@@H](COC(=O)C(N)C(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(O)[C@@H](COC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1 Chemical compound CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(O)[C@@H](COC(=O)C(N)C(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(O)[C@@H](COC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1 NRIHVLQKPRYWEH-XORYCLPQSA-N 0.000 description 1
- STUUHVHTXFJLFT-KCIZQBNTSA-N CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(N)C(C)C)[C@@H](CO)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O4)C(=O)N=C3O2)C=C1 Chemical compound CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(N)C(C)C)[C@@H](CO)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O4)C(=O)N=C3O2)C=C1 STUUHVHTXFJLFT-KCIZQBNTSA-N 0.000 description 1
- BIFUTJWOVGWTIL-RWHLUHTPSA-N CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(N)C(C)C)[C@@H](COC(=O)C(N)C(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)[C@@H](COC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1 Chemical compound CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(N)C(C)C)[C@@H](COC(=O)C(N)C(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)[C@@H](COC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1 BIFUTJWOVGWTIL-RWHLUHTPSA-N 0.000 description 1
- CWNFCKPWJRBQQT-JCFDSLKQSA-N CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(N)C(C)C)[C@@H](COC(=O)C(N)C(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)[C@@H](COC(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)O4)C(=O)N=C3O2)C=C1 Chemical compound CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(N)C(C)C)[C@@H](COC(=O)C(N)C(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)[C@@H](COC(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)O4)C(=O)N=C3O2)C=C1 CWNFCKPWJRBQQT-JCFDSLKQSA-N 0.000 description 1
- WGUQDNWHRUFHCB-GXXMSPCESA-N CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(N)C(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O4)C(=O)N=C3O2)C=C1 Chemical compound CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(N)C(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O4)C(=O)N=C3O2)C=C1 WGUQDNWHRUFHCB-GXXMSPCESA-N 0.000 description 1
- JGRBLJJILCAYOB-OBZHLDBPSA-N CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(N)C(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O4)C(=O)N=C3O2)C=C1 Chemical compound CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(N)C(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O4)C(=O)N=C3O2)C=C1 JGRBLJJILCAYOB-OBZHLDBPSA-N 0.000 description 1
- BPTLFJZQUQVFIJ-QJMQRMBDSA-N CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)C5CCCC5C(=O)C(N)C(C)C)C(C)C)[C@@H](COC(=O)C(NC(=O)C5CCCC5C(=O)C(N)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)[C@@H](COC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1 Chemical compound CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)C5CCCC5C(=O)C(N)C(C)C)C(C)C)[C@@H](COC(=O)C(NC(=O)C5CCCC5C(=O)C(N)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)[C@@H](COC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1 BPTLFJZQUQVFIJ-QJMQRMBDSA-N 0.000 description 1
- NUKGEXFQDWFXSG-NCGPSZQOSA-N CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)[C@@H](CO)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O4)C(=O)N=C3O2)C=C1 Chemical compound CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)[C@@H](CO)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(/C2=C/C3=CN([C@H]4CC(OC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)[C@@H](CO[Si](C)(C)C(C)(C)C)O4)C(=O)N=C3O2)C=C1 NUKGEXFQDWFXSG-NCGPSZQOSA-N 0.000 description 1
- WOACIDHJXAVVJN-UHFFFAOYSA-N CCCCCC1=CC=C(C2=CC3=CN(C4CC(O)C(COC(=O)C(N)C(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(C2=CC3=CN(C4CC(OC(=O)C(N)C(C)C)C(CO)O4)C(=O)N=C3O2)C=C1 Chemical compound CCCCCC1=CC=C(C2=CC3=CN(C4CC(O)C(COC(=O)C(N)C(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(C2=CC3=CN(C4CC(OC(=O)C(N)C(C)C)C(CO)O4)C(=O)N=C3O2)C=C1 WOACIDHJXAVVJN-UHFFFAOYSA-N 0.000 description 1
- YFPUNUUMWCTYET-MAOHZMIYSA-N CCCCCC1=CC=C(C2=CC3=CN([C@H]4CC(O)[C@@H](COC(=O)C(NC(=O)C5CCCC5C(=O)C(N)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(C2=CC3=CN([C@H]4CC(O)[C@@H](COC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1 Chemical compound CCCCCC1=CC=C(C2=CC3=CN([C@H]4CC(O)[C@@H](COC(=O)C(NC(=O)C5CCCC5C(=O)C(N)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1.CCCCCC1=CC=C(C2=CC3=CN([C@H]4CC(O)[C@@H](COC(=O)C(NC(=O)C5CCCC5C(=O)C(NC(=O)OCC5C6=C(C=CC=C6)C6=C5C=CC=C6)C(C)C)C(C)C)O4)C(=O)N=C3O2)C=C1 YFPUNUUMWCTYET-MAOHZMIYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 1
- 229930182831 D-valine Natural products 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- FRJIAZKQGSCKPQ-FSPLSTOPSA-N His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1 FRJIAZKQGSCKPQ-FSPLSTOPSA-N 0.000 description 1
- LNCFUHAPNTYMJB-IUCAKERBSA-N His-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CN=CN1 LNCFUHAPNTYMJB-IUCAKERBSA-N 0.000 description 1
- RCFDOSNHHZGBOY-ACZMJKKPSA-N Ile-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(O)=O RCFDOSNHHZGBOY-ACZMJKKPSA-N 0.000 description 1
- BBIXOODYWPFNDT-CIUDSAMLSA-N Ile-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(O)=O BBIXOODYWPFNDT-CIUDSAMLSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QOOWRKBDDXQRHC-BQBZGAKWSA-N L-lysyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN QOOWRKBDDXQRHC-BQBZGAKWSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- HSQGMTRYSIHDAC-BQBZGAKWSA-N Leu-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(O)=O HSQGMTRYSIHDAC-BQBZGAKWSA-N 0.000 description 1
- VTJUNIYRYIAIHF-IUCAKERBSA-N Leu-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O VTJUNIYRYIAIHF-IUCAKERBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 description 1
- WEQJQNWXCSUVMA-RYUDHWBXSA-N Phe-Pro Chemical compound C([C@H]([NH3+])C(=O)N1[C@@H](CCC1)C([O-])=O)C1=CC=CC=C1 WEQJQNWXCSUVMA-RYUDHWBXSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108700015930 Prolyl Oligopeptidases Proteins 0.000 description 1
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 1
- SSJMZMUVNKEENT-IMJSIDKUSA-N Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CO SSJMZMUVNKEENT-IMJSIDKUSA-N 0.000 description 1
- WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- AKRQHOWXVSDJEF-UHFFFAOYSA-N heptane-1-sulfonic acid Chemical compound CCCCCCCS(O)(=O)=O AKRQHOWXVSDJEF-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical class C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 108010071185 leucyl-alanine Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108010024607 phenylalanylalanine Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003239 susceptibility assay Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
Definitions
- the present invention provides improvements in or relating to compositions for the treatment or prophylaxis of viral infections such, for example, as those caused by the Varicella Zoster virus (VZV).
- VZV Varicella Zoster virus
- Varicella Zoster virus is the aetiological agent of chickenpox and shingles, which can cause considerable human illness and suffering.
- WO 01/83501 A1 discloses certain nucleoside analogues with potent activity against Varicella Zoster virus (VZV), said nucleoside analogues having the general formula (I):
- Ar is an, optionally substituted, aromatic ring system, the aromatic ring system comprising one six-membered aromatic ring or two fused six-membered aromatic rings;
- R 10 and R 11 are each independently selected from the group comprising hydrogen, alkyl, cycloalkyl, halogens, amino, alkylamino, dialkylamino, nitro, cyano, alkyloxy, aryloxy, thiol, alkylthiol, arylthiol, aryl;
- Q is selected from the group comprising O, S and CY 2 , where Y may be the same or different and is selected from H, alkyl and halogens;
- X is selected from the group comprising O, NH, S, N-alkyl, (CH 2 ) m where m is 1 to 10, and CY 2 where Y may be the same or different and is selected from hydrogen, alkyl and halogens;
- Z is selected from the group comprising O, S, NH, and N-alkyl
- T is selected from the group comprising OH, H, halogens, O-alkyl, O-acyl, O-aryl, CN, NH 2 and N 3 ;
- T′ is selected from the group comprising H and halogens and, where more than one T′ is present, they may be the same or different;
- T′′ is selected from the group comprising H and halogens
- W is selected from the group comprising H, a phosphate group and a phosphonate group
- W may be modified to provide any pharmacologically acceptable salt or derivative of H, phosphate or phosphonate.
- WO 01/83501 A1 further discloses that when W is selected from phosphates and derivatives thereof and phosphonates and derivatives thereof, W may be modified to provide a pro-drug of the compound of formula (I).
- WO 2004/098644 A1 discloses conjugates of therapeutic agents with a peptidic moiety in which the conjugate is cleavable by a dipeptidyl-peptidase, such as CD26.
- conjugation of the therapeutic agents is calculated to ameliorate their solubility and bioavailability, and may be used to modulate the protein binding of a therapeutic compound and to target specific sites in a mammal.
- CD26 dipeptidyl-peptidase IV (EC 3.4.14.5) in its membrane bound or free form; synonyms for CD26 are DPPIV, DPP4, CD26/DPPIV, or ADCP2 (adenosine deaminase complexing protein 2).
- a dipeptidyl-peptidase is an enzyme with a dipeptidyl aminopeptidase activity, i.e., removing a dipeptide from the amino-terminal side of a substrate site by cleavage of the second CO—NH amide bond in the substrate.
- CD26 Other enzymes than CD26 with a comparable activity and proteolytic specificity as CD26 (i.e., prolyloligopeptidases) are referred to by “dipeptidyl-peptidase(s)”. “Dipeptidylpeptidase IV” refers to CD26.
- a therapeutic compound having, or being bound to a linker A m having an amino group, particularly a terminal primary or secondary amino group, capable of binding with the carboxyl group of an amino acid is linked to an oligopeptide consisting of a general structure H—[X—Y] n , wherein X is an amino acid, n is between 1 and 5 and Y is an amino acid selected from proline, alanine, hydroxyproline, dihydroxyproline, thiazolidinecarboxylic acid (thioproline), dehydroproline, pipecolic acid (L-homoproline), azetidinecarboxylic acid, aziridinecarboxylic acid, glycine, serine, valine, leucine, isoleucine and threonine, and wherein the binding between the carboxy terminus of H—[X—Y] n and the amino group of the therapeutic compound or its linker occurs via an amide.
- the peptide has between two to five CD26 cleavable repeats.
- the number m of amino acids in the linker A m is between 1 and 15, more particularly between 1 to 3.
- A may be any amino acid. More particularly, m is 1 and A is valine.
- X is O, S, NH or CH 2 ,
- Y is O, S or NH
- Z is O, S or CH 2 ,
- R 1 is C 1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl, and
- R 13 and R 14 are OH, and the other of R 14 and R 13 is a neutral, non-polar amino acid moiety,
- R 13 or R 14 is valine, especially L-valine.
- the compound of PCT/GB2007/001677 is especially suitable for oral administration. It has been shown that the oral bioavailability of drugs can be mediated by amino acid prodrug derivatives containing an amino acid, preferably in the L-configuration. L-valine seems to have the optimal combination of chain length and branching at the ⁇ -carbon of the amino acid for intestinal absorption. hPEPT-1 has been found to be implicated as the primary absorption pathway of increased systemic delivery of L-valine ester prodrugs. The hPEPT-1 transport needs to interact optimally with a free NH 2 , a carbonyl group and a lipophylic entity, and may form additional H-bridges with its target molecule.
- Preferred compounds according to PCT/GB2007/001677 are:
- Compound 5 was found to have improved bioavailability after oral dosing in mice as compared to Compound 1 of WO 01/83501 A1 (see above).
- X is O, S, NH or CH 2 ;
- Y is O, S or NH
- Z is O, S or CH 2 ;
- R 1 is C 1-8 alkyl, especially C 1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl; at least one of R 2 and R 3 is H—[R 4 -R 5 ] n —R 6 —, in which:
- R 3 and R 2 is H—[R 4 -R 5 ] n —R 6 — or H; or
- one of R 2 and R 3 is H—[R 4 -R 5 ] n —R 6 — and the other is H.
- both of R 2 and R 3 may be H—[R 4 -R 5 ] n —R 6 —.
- R 4 , R 5 , R 6 and n are selected independently for R 2 and R 3 respectively.
- R 2 and R 3 may be the same.
- the compound of the present invention is cleavable by CD26.
- the H—[R 4 -R 5 ] n — has a free amino-terminus, i.e., an unmodified NH 2 group.
- n may be 2-5, and in particular the —[R 4 -R 5 ] n — oligopeptide may be a tetrapeptide or a hexapeptide, it being understood that, in each R 4 -R 5 unit, R 4 and R 5 are selected independently of the one or more other units.
- n 1, H—[R 4 -R 5 ] n —R 6 thus being a tripeptide moiety.
- R 4 and R 5 may be L-amino acids, although, in some embodiments, one or both of R 4 and R 5 may be employed in their D-forms. Further, R 4 and R 5 are suitably naturally occurring amino acids.
- R 4 may be selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
- R 4 is valine
- R 5 may be selected from proline, alanine, glycine, serine, valine and leucine.
- R 5 is proline or alanine.
- the oligopeptide —[R 4 -R 5 ]— is selected from Val-Pro, Asp-Pro, Ser-Pro, Lys-Pro, Arg-Pro, His-Pro, Phe-Pro, Ile-Pro, Leu-Pro, Val-Ala, Asp-Ala, Ser-Ala, Lys-Ala, Arg-Ala, His-Ala, Phe-Ala, Ile-Ala and Leu-Ala.
- said oligopeptide is Val-Pro.
- R 6 is:
- R 7 , R 8 and R 9 are each independently H or C 1-3 alkyl, especially C 1-2 alkyl.
- R 9 is preferably H.
- R 6 may be valine, leucine, isoleucine or alanine.
- R 6 is valine.
- R 6 may be L-valine, D-valine or D,L-valine; preferably R 6 is L-valine.
- R 2 and R 3 are the same, and both are H-Val-Pro-Val-.
- X, Y and Z are preferably all O.
- Particularly preferred compounds according to the present invention are:
- X is O, S, NH or CH 2 ;
- Y is O, S or NH
- Z is O, S or CH 2 ;
- R 1 is C 1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl;
- R 13 and R 14 is a neutral, non-polar amino acid moiety having a free amino terminus
- R 14 and R 13 is H, the resulting hydroxyl group being optionally protected, or a neutral, non-polar amino acid moiety;
- Said amino-protecting group may comprise a 3. 9-fluorenylmethoxycarbonyl (Fmoc) protecting group, but other, suitable amino-protecting groups are known and available to those skilled in the art.
- the resulting hydroxyl group may be protected with a suitable hydroxyl-protecting group such, for example, as tert-butyldimethylsilyl chloride.
- a suitable hydroxyl-protecting group such as tert-butyldimethylsilyl chloride.
- Other hydroxyl-protecting groups will be known to those skilled in the art.
- Said compound of formula (II) may be synthesised by esterifying a compound of formula (IV):
- said amino acid may have the formula (V):
- R 7 , R 8 and R 9 are as defined above.
- R 13 and/or R 14 are valine, especially L-valine.
- the ⁇ -amino group is suitably protected during the esterification reaction.
- said amino acid may be protected using a 3. 9-fluorenylmethoxycarbonyl (Fmoc) protecting group.
- Fmoc 9-fluorenylmethoxycarbonyl
- the Fmoc group may be introduced under Schotten-Baumen conditions. It is exceptionally stable towards acid.
- the cleavage of this group may be base catalysed (ammonia, piperidine, morpholine, DBU) undergoing an E1 ⁇ -elimination mechanism.
- the esterification reaction conditions may be suitably adjusted as desired to obtain the 3′- or 5′-ester or the 3′,5′-diester.
- the 5′-OH group may be protected as described above using a suitable hydroxyl-protecting group such, for example, as tert-butyldimethylsilyl chloride, which may be removed after completion of the esterification reaction or left in situ for the subsequent conjugation reaction with the protected oligopeptide.
- the 5′-esterification is preferably carried out under Mitsunobu conditions 1 : 1 Mitsunobu, Synthesis, January 1981: 1-28
- the hydrochloride salt may be prepared by treatment of the ester (VI) with a solution of HCl in THF.
- the 3′- and 3′,5′-esterification reactions may be carried out using the conventional coupling method (DCC/DMAP) known to those skilled in the art of in acyclic nucleosides.
- DCC/DMAP conventional coupling method
- the 3′,5′-diesterification may be performed in DMF by admixing to the compound of formula (IV) 4-dimethylaminopyridine, Fmoc-R 7 R 8 CH 9 (NH 2 )COOH and N,N′-dicyclohexyl-carbodiimide DCC in succession, followed by washing the resultant white solid.
- DCC/DMAP conventional coupling method known to those skilled in the art of in acyclic nucleosides. 2
- the 3′,5′-diesterification may be performed in DMF by admixing to the compound of formula (IV) 4-dimethylaminopyridine, Fmoc-R 7 R 8 CH 9 (NH 2 )COOH and N,N′-dicyclohe
- 3′-esterification may be performed in a similar manner by reacting the 5′-protected hydroxyl compound of formula (IV) dissolved in DMF with 4-dimethylaminopyridine, Fmoc-R 7 R 8 CH 9 (NH 2 )COOH and N,N′ dicyclohexyl-carbodiimide DCC in succession.
- R 1 is n-pentyl
- X, Y and Z are all O
- R 7 and R 8 are both methyl.
- the compound of the present invention has advantageous pharmacokinetic (PK) properties and improved bioavailability as compared to Compound 1 of WO 01/83501 A1.
- PK pharmacokinetic
- the conjugation of a dipeptide moiety to the free amino terminus of the valyl ester of PCT/GB2007/001677 appears not to impair the bioavailability of the compound.
- the compound of the invention exhibits unexpectedly high solubility in water as compared with Compound 1.
- Bioavailability is often a key factor in the practical application of a drug as a therapeutic agent and compounds that demonstrate enhanced PK and/or solubility generally have improved potency in vivo over compounds with less favorable PK properties even though their in vitro potency may be similar.
- Such compounds i.e., derivatives of known in vitro active compounds, are often referred to as prodrugs.
- Novel Compound 7 is an example of such a prodrug.
- a pharmaceutically acceptable salt of the compound of the invention may comprise a counter-ion that is pharmaceutically physiologically acceptable.
- the pharmaceutically or physiologically acceptable acid addition salt forms that the compound of the invention is able to form can conveniently be prepared using the appropriate acids such, for example, as inorganic acids such as hydrohalic acids, e.g., hydrochloride or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such, for example, as acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfuric, ethanesulfuric, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-amino-salicylic, pamoic and the like acids.
- said acid addition salt forms can be converted by treatment with an appropriate base into the free base form.
- the compound of the invention containing an acidic proton may also be converted into its non-toxic metal or amine addition salt by treatment with appropriate organic and inorganic bases.
- Appropriate base salt forms comprise, for example, the ammonium salts, quaternary ammonium salts, the alkali and earth alkaline metal salts, e.g., the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g., the benzathine, N-methyl, -D-glucamine, hydrabamine salts and bases, and salts with amino acids, such as, for example, arginine, lysine and the like.
- said base addition forms can be converted by treatment with an appropriate acid into the free acid form.
- salt as used herein also comprises the hydrate and solvent addition forms that the compound of the invention is able to form. Examples of such forms are, e.g., hydrates, alcoholate and the like.
- salt also comprehends the quaternisation of the nitrogen atoms of the compound.
- a basic nitrogen can be quaternised with any agent known to those skilled in the art including, for instance, lower alkyl halides, dialkyl sulfates, long chain halides and arylalkyl halides.
- the compound of the invention may also exist in its tautomeric forms. Such forms, although not explicitly indicated in the above formula (III), are intended to be included within the scope of the present invention.
- a compound according to the present invention for use in a method of treatment, particularly the prophylaxis or treatment of a viral infection.
- said compound may be provided for use in the treatment or prophylaxis of an infection with the Varicella Zoster virus.
- a compound according to the present invention in the manufacture of a medicament for the prophylaxis or treatment of viral infection, especially a viral infection caused by the Varicella Zoster virus, e.g., chicken pox or shingles.
- a method of prophylaxis or treatment of viral infection comprising administration to a human or non-human animal patient in need of such treatment an effective amount of a compound according to the present invention.
- a pharmaceutical composition comprising a compound of the present invention in combination with a pharmaceutically acceptable excipient.
- Medicaments embodying the present invention can be administered by oral, enteral or parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
- enteral or parenteral routes including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
- compounds embodying the present invention will generally be provided in the form of tablets or capsules, as a powder or granules, or as an aqueous solution or suspension.
- Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives.
- suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents.
- Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc.
- the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
- Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.
- Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- compounds embodying the present invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity.
- Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
- Aqueous suspensions embodying the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such as lecithin.
- Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.
- a suitable dose will be in the range of 0.001 to 300 mg per kilogram body weight of the recipient per day, preferably in the range of 0.01 to 25 mg per kilogram body weight per day, and most preferably in the range 0.05 to 10 mg per kilogram body weight per day.
- the desired dose may be presented as two, three, four, five or six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing 0.1 to 1500 mg, preferably 0.2 to 1000 mg, and most preferably 0.5 to 700 mg of active ingredient per unit dosage form.
- a dose of 100-500 mg of the compound of the present invention may be administered once per day.
- FIG. 1 is a graph showing the bioavailability (in arbitrary units) of Compounds 1, 5 and 7 at certain times after oral gavage.
- FIG. 2 shows the water-solubility of Compounds 1, 5 and 7.
- Fmoc-Compound 8 may be fully deprotected to form Compound 3 of PCT/GB2007/00167.
- Fmoc-Compound 8 (128 mg, 0.15 mmol) was dissolved in MeOH (1 ml) and a solution of HCl 0.1N in MeOH (1.85 ml, 0.19 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours and the solvent was evaporated to dryness. The residue was dissolved in dichloromethane (40 mL) and washed with a 10% aqueous NaHCO 3 (3 ⁇ 20 mL).
- mice A study was conducted with Compounds 1, 5 and 7 to compare the relative bioavailability of Compound 1 after oral dosing in mice.
- Three groups of female mice received equimolar doses of Compound 1 (25 mg/kg), 5 (31.25 mg/kg; equivalent to 25 mg/kg of Compound 1) or 7 (41.8 mg/kg; equivalent to 25 mg/kg of compound 1) as a single oral gavage dose formulated in 0.5% carboxymethylcellulose.
- the mice were serially sacrificed at time-points ranging from 0.25 to 3 hours post dosing (3 mice/time-point), and plasma samples were taken and analyzed for Compound 1 concentration using a non-validated HPLC method with fluorescence detection. Results are reported as relative peak areas for Compound 1, which assumes that peak area is directly proportional to concentration over these ranges of concentrations.
- Plasma concentrations of Compound 1 were much higher in mice receiving Compounds 5 and 7 as compared to mice receiving Compound 1. Note that although these data do not provide absolute plasma concentrations of Compound 1, one can estimate from the peak areas that Compound 5 increases the oral bioavailability of Compound 1 by approximately 8-fold and Compound 7 by approximately 12-fold (as estimated by the AUC values).
- test compounds have been evaluated for their substrate activity against purified CD26, human serum (HS), and bovine serum (BS) in Eppendorf tubes.
- the 400 ⁇ L reaction mixture contained 50 ⁇ M of test compound in PBS (containing 0.1% DMSO).
- the reaction was started by the addition of purified CD26 (1.5 mU) or 20% of HS (in PBS) or BS (in PBS) at 37° C.
- 100 ⁇ L was withdrawn from the reaction mixture, added to 200 ⁇ L methanol, and put on ice for ⁇ 10 min. Then, the mixture was centrifuged at 13,000 rpm for 5 min at 4° C. and 250 ⁇ L of supernatant was analyzed by HPLC on a reverse phase RP-8 column, using following gradients:
- Gradient A (Buffer A: 50 mM NaH 2 PO 4 +5 mM heptane-sulfonic acid pH 3.2; buffer B: acetonitrile): 2 min 98% A+2% B; 6 min linear gradient to 80% A+20% B; 2 min linear gradient to 75% A+25% B; 2 min linear gradient to 65% A+35% B; 18 min linear gradient to 50% A+50% B; 5 min 50% A+50% B; 5 min linear gradient to 98% A+2% B; 5 min equilibration at 98% A+2% B.
- the objective of this study was to compare the antiviral activity of Compounds 1, 3, 5, 7 and 9 in HEL cells inoculated with VZV strains. Antiviral activity was assessed as the ability of Compounds 1, 3, 5, 7 and 9 to reduce viral plaque formation after incubation periods of 5 days as compared to untreated control cultures. The results of the antiviral efficacy studies showing comparable efficacy between the three compounds are shown in Tables 3a and 3b below.
- VZV-drug susceptibility assays were performed on confluent HEL cells in 96-well microtiter plates. Monolayers were infected with 20 PFU of cell-associated virus per well. For each assay, virus controls (infected-untreated cells) were included. After a 2-hour incubation period, the virus inoculum was removed and the media replaced by the different dilutions (in duplicate) of the tested molecules. Serial dilutions of test compounds were incubated with the infected monolayers for 5 days. After the 5-day incubation period, the cells were fixed and stained with Giemsa, and the level of virus-induced cytopathic effect was determined by counting the number of plaques for each dilution. Activity was expressed as EC 50 (effective compound concentration required to reduce virus-plaque formation by 50%) compared to the untreated control.
- Compounds 7 and 9 and 5 and 3 are active in VZV-infected HEL cell cultures. They lose antiviral activity against VZV/TK-. Neither of them is cytotoxic or cytostatic at concentrations that largely exceed the antiviral concentrations.
- the water-solubility of Compound 7 was determined by HPLC analysis and compared with that of Compound 5 and parent Compound 1.
- HPLC was carried out on a Waters 484 System using Novapack C18 reverse phase column. Flow rate: 1 mL/min. Detection: UV 254 nm.
- Gradient solvent system AlB acetonitrile/water: initial 15% A+85% B; 5 min linear gradient to 25% A+75% B; 5 min linear gradient to 35% A+65% B; 10 min linear gradient to 45% A+55% B; 5 min linear gradient to 60% A+40% B and 5 min linear gradient to 100% A.
- solubility and partition coefficients of the prodrugs and parent compound are provided in Table 4 below. Predicted partition coefficient values suggest that lipophilicity can be significantly reduced from 3.24 to 1.60 or 0.70 upon introduction of the valyl or tripeptidyl moiety.
- the prodrugs exhibited higher water-solubility than the parent drug as shown in FIG. 2 .
- Compound 7 prodrug improved the water-solubility (1.27 mg/mL) more than 57-fold in comparison with the parent Compound 1 (0.022 mg/mL). This result suggests that the CD26 prodrug approach could be useful for increasing the water-solubility of hydrophobic drugs.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 13/971,631, filed on Aug. 20, 2013, which is a divisional application of U.S. patent application Ser. No. 12/676,394, filed on Jun. 8, 2010 (now U.S. Pat. No. 8,513,215), which is a national stage application, filed under 35 U.S.C. §371, of International Application No. PCT/EP2008/007009, filed on Aug. 27, 2008, which claims priority to, and the benefit of, GB 0717526.8, filed on Sep. 7, 2007, the contents of each of which are incorporated herein by reference in their entireties.
- The present invention provides improvements in or relating to compositions for the treatment or prophylaxis of viral infections such, for example, as those caused by the Varicella Zoster virus (VZV). Varicella Zoster virus is the aetiological agent of chickenpox and shingles, which can cause considerable human illness and suffering.
- WO 01/83501 A1, the contents of which are incorporated herein by reference, discloses certain nucleoside analogues with potent activity against Varicella Zoster virus (VZV), said nucleoside analogues having the general formula (I):
- wherein:
- Ar is an, optionally substituted, aromatic ring system, the aromatic ring system comprising one six-membered aromatic ring or two fused six-membered aromatic rings;
- R10 and R11 are each independently selected from the group comprising hydrogen, alkyl, cycloalkyl, halogens, amino, alkylamino, dialkylamino, nitro, cyano, alkyloxy, aryloxy, thiol, alkylthiol, arylthiol, aryl;
- Q is selected from the group comprising O, S and CY2, where Y may be the same or different and is selected from H, alkyl and halogens;
- X is selected from the group comprising O, NH, S, N-alkyl, (CH2)m where m is 1 to 10, and CY2 where Y may be the same or different and is selected from hydrogen, alkyl and halogens;
- Z is selected from the group comprising O, S, NH, and N-alkyl;
- U″ is H and U′ is selected from H and CH2T, or U′ and U″ are joined so as to form a ring moiety including Q wherein U′—U″ together is respectively selected from the group comprising CTH-CT′T″ and CT=CT, so as to provide ring moieties selected from the group comprising:
- wherein T is selected from the group comprising OH, H, halogens, O-alkyl, O-acyl, O-aryl, CN, NH2 and N3;
- T′ is selected from the group comprising H and halogens and, where more than one T′ is present, they may be the same or different;
- T″ is selected from the group comprising H and halogens; and
- W is selected from the group comprising H, a phosphate group and a phosphonate group;
- with the proviso that when T is OAc and T′ and T″ are present and are H, Ar is not 4-(2-benzoxazolyl) phenyl.
- According to WO 01/83501 A1, W may be modified to provide any pharmacologically acceptable salt or derivative of H, phosphate or phosphonate. WO 01/83501 A1 further discloses that when W is selected from phosphates and derivatives thereof and phosphonates and derivatives thereof, W may be modified to provide a pro-drug of the compound of formula (I).
-
Compounds 1 and 2 below are particularly preferred compounds according to WO 01/83501 A1: - The development of many promising therapeutic agents is hindered by their poor water solubility.
- WO 2004/098644 A1, the contents of which are also incorporated herein by reference, discloses conjugates of therapeutic agents with a peptidic moiety in which the conjugate is cleavable by a dipeptidyl-peptidase, such as CD26. Such conjugation of the therapeutic agents is calculated to ameliorate their solubility and bioavailability, and may be used to modulate the protein binding of a therapeutic compound and to target specific sites in a mammal.
- By “CD26” as used herein is meant dipeptidyl-peptidase IV (EC 3.4.14.5) in its membrane bound or free form; synonyms for CD26 are DPPIV, DPP4, CD26/DPPIV, or ADCP2 (adenosine deaminase complexing protein 2). A dipeptidyl-peptidase is an enzyme with a dipeptidyl aminopeptidase activity, i.e., removing a dipeptide from the amino-terminal side of a substrate site by cleavage of the second CO—NH amide bond in the substrate. Other enzymes than CD26 with a comparable activity and proteolytic specificity as CD26 (i.e., prolyloligopeptidases) are referred to by “dipeptidyl-peptidase(s)”. “Dipeptidylpeptidase IV” refers to CD26.
- According to WO 2004/098644 A1, a therapeutic compound having, or being bound to a linker Am having an amino group, particularly a terminal primary or secondary amino group, capable of binding with the carboxyl group of an amino acid is linked to an oligopeptide consisting of a general structure H—[X—Y]n, wherein X is an amino acid, n is between 1 and 5 and Y is an amino acid selected from proline, alanine, hydroxyproline, dihydroxyproline, thiazolidinecarboxylic acid (thioproline), dehydroproline, pipecolic acid (L-homoproline), azetidinecarboxylic acid, aziridinecarboxylic acid, glycine, serine, valine, leucine, isoleucine and threonine, and wherein the binding between the carboxy terminus of H—[X—Y]n and the amino group of the therapeutic compound or its linker occurs via an amide. In one embodiment, the peptide has between two to five CD26 cleavable repeats. In another embodiment, the number m of amino acids in the linker Am is between 1 and 15, more particularly between 1 to 3. A may be any amino acid. More particularly, m is 1 and A is valine.
- International patent application no. PCT/GB2007/001677, which is comprised in the state of the art according to EPCa.54(3) and the contents of which are also incorporated herein by reference, discloses a compound of general formula (II):
- wherein X is O, S, NH or CH2,
- Y is O, S or NH,
- Z is O, S or CH2,
- R1 is C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl, and
- one of R13 and R14 is OH, and the other of R14 and R13 is a neutral, non-polar amino acid moiety,
- or a pharmaceutically acceptable salt or hydrate thereof.
- Preferably R13 or R14 is valine, especially L-valine.
- The compound of PCT/GB2007/001677 is especially suitable for oral administration. It has been shown that the oral bioavailability of drugs can be mediated by amino acid prodrug derivatives containing an amino acid, preferably in the L-configuration. L-valine seems to have the optimal combination of chain length and branching at the β-carbon of the amino acid for intestinal absorption. hPEPT-1 has been found to be implicated as the primary absorption pathway of increased systemic delivery of L-valine ester prodrugs. The hPEPT-1 transport needs to interact optimally with a free NH2, a carbonyl group and a lipophylic entity, and may form additional H-bridges with its target molecule.
- Preferred compounds according to PCT/GB2007/001677 are:
-
Compound 5 was found to have improved bioavailability after oral dosing in mice as compared toCompound 1 of WO 01/83501 A1 (see above). - It has now been found that by conjugating the compound of PCT/GB2007/001677 with a CD26 cleavable oligopeptide, a surprisingly great improvement in the solubility of the compound as compared with the non-derivatised nucleoside analogue of general formula (I) according to WO 01/83501 A1 may be obtained, without adversely affecting the bioavailability of such compound. Indeed, the bioavailability may even be increased. Further, the conjugated compound retains comparable antiviral activity to the non-derivatised nucleoside analogue of general formula (I).
- According to one aspect of the present invention, therefore, there is provided a compound of the general formula (III):
- wherein X is O, S, NH or CH2;
- Y is O, S or NH;
- Z is O, S or CH2;
- R1 is C1-8 alkyl, especially C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl; at least one of R2 and R3 is H—[R4-R5]n—R6—, in which:
-
- H—[R4-R5]n— comprises an oligopeptide, R4 being an amino acid and R5 being an amino acid selected from proline, alanine, hydroxyproline, dihydroxyproline, thiazolidinecarboxylic acid (thioproline), dehydroproline, pipecolic acid (L-homoproline), azetidinecarboxylic acid, aziridinecarboxylic acid, glycine, serine, valine, leucine, isoleucine and threonine,
- R6 is a neutral, non-polar amino acid moiety that is bonded to R5 by a peptide bond, and
- n is 1, 2, 3, 4 or 5; and
- the other of R3 and R2 is H—[R4-R5]n—R6— or H; or
- a pharmaceutically acceptable salt thereof.
- In some embodiments, one of R2 and R3 is H—[R4-R5]n—R6— and the other is H. Alternatively, both of R2 and R3 may be H—[R4-R5]n—R6—. Where both R2 and R3 are H—[R4-R5]n—R6—, R4, R5, R6 and n are selected independently for R2 and R3 respectively. However, in some embodiments, R2 and R3 may be the same.
- The compound of the present invention is cleavable by CD26. The H—[R4-R5]n— has a free amino-terminus, i.e., an unmodified NH2 group.
- In some embodiments n may be 2-5, and in particular the —[R4-R5]n— oligopeptide may be a tetrapeptide or a hexapeptide, it being understood that, in each R4-R5 unit, R4 and R5 are selected independently of the one or more other units.
- Preferably, however, n=1, H—[R4-R5]n—R6 thus being a tripeptide moiety.
- One or both of R4 and R5 may be L-amino acids, although, in some embodiments, one or both of R4 and R5 may be employed in their D-forms. Further, R4 and R5 are suitably naturally occurring amino acids.
- Suitably, R4 may be selected from alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine.
- Advantageously, R4 is valine.
- Suitably, R5 may be selected from proline, alanine, glycine, serine, valine and leucine.
- Advantageously R5 is proline or alanine.
- Suitably, the oligopeptide —[R4-R5]— is selected from Val-Pro, Asp-Pro, Ser-Pro, Lys-Pro, Arg-Pro, His-Pro, Phe-Pro, Ile-Pro, Leu-Pro, Val-Ala, Asp-Ala, Ser-Ala, Lys-Ala, Arg-Ala, His-Ala, Phe-Ala, Ile-Ala and Leu-Ala.
- Preferably, said oligopeptide is Val-Pro.
- Preferably said neutral, non-polar amino acid moiety R6 is:
- in which R7, R8 and R9 are each independently H or C1-3 alkyl, especially C1-2 alkyl.
- R9 is preferably H.
- In some embodiments, R6 may be valine, leucine, isoleucine or alanine.
- Preferably R6 is valine. R6 may be L-valine, D-valine or D,L-valine; preferably R6 is L-valine.
- In some preferred embodiments, R2 and R3 are the same, and both are H-Val-Pro-Val-.
- Further, X, Y and Z are preferably all O.
- Particularly preferred compounds according to the present invention are:
- According to another aspect of the present invention there is provided a method of synthesising the compound of the invention, said method comprising conjugating a compound of formula (II):
- wherein X is O, S, NH or CH2;
- Y is O, S or NH;
- Z is O, S or CH2;
- R1 is C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl;
- at least one of R13 and R14 is a neutral, non-polar amino acid moiety having a free amino terminus; and
- the other of R14 and R13 is H, the resulting hydroxyl group being optionally protected, or a neutral, non-polar amino acid moiety;
- with a protected oligopeptide of formula Z′—[R4-R5]n—OH to form a peptide bond between R5 and at least one of R13 or R14, wherein R4 and R5 are as defined above and Z′ is an amino-protecting group to protect the free amino terminus, and thereafter removing said protecting group.
- Said amino-protecting group may comprise a 3. 9-fluorenylmethoxycarbonyl (Fmoc) protecting group, but other, suitable amino-protecting groups are known and available to those skilled in the art.
- When R13 is H, the resulting hydroxyl group may be protected with a suitable hydroxyl-protecting group such, for example, as tert-butyldimethylsilyl chloride. Other hydroxyl-protecting groups will be known to those skilled in the art. Once the conjugation reaction between the compound of formula (II) and the dipeptide has been completed, the hydroxyl-protecting group may be removed to expose the free 5′-OH group.
- Said compound of formula (II) may be synthesised by esterifying a compound of formula (IV):
- with a protected neutral, non-polar amino acid, wherein R1, X, Y and Z are as defined above to obtain the 3′- or 5′-ester or 3′,5′-diester.
- In some embodiments, said amino acid may have the formula (V):
- wherein R7, R8 and R9 are as defined above.
- Preferably R13 and/or R14 are valine, especially L-valine.
- The α-amino group is suitably protected during the esterification reaction. In some embodiments, where R9 is H, said amino acid may be protected using a 3. 9-fluorenylmethoxycarbonyl (Fmoc) protecting group. Other suitable protecting groups are known and available to those skilled in the art.
- The Fmoc group may be introduced under Schotten-Baumen conditions. It is exceptionally stable towards acid. The cleavage of this group may be base catalysed (ammonia, piperidine, morpholine, DBU) undergoing an E1 β-elimination mechanism.
- The esterification reaction conditions may be suitably adjusted as desired to obtain the 3′- or 5′-ester or the 3′,5′-diester. Where the 3′-(mono) ester is desired, the 5′-OH group may be protected as described above using a suitable hydroxyl-protecting group such, for example, as tert-butyldimethylsilyl chloride, which may be removed after completion of the esterification reaction or left in situ for the subsequent conjugation reaction with the protected oligopeptide.
- The 5′-esterification is preferably carried out under Mitsunobu conditions1: 1 Mitsunobu, Synthesis, January 1981: 1-28
- The hydrochloride salt may be prepared by treatment of the ester (VI) with a solution of HCl in THF.
- The 3′- and 3′,5′-esterification reactions may be carried out using the conventional coupling method (DCC/DMAP) known to those skilled in the art of in acyclic nucleosides.2 For example, the 3′,5′-diesterification may be performed in DMF by admixing to the compound of formula (IV) 4-dimethylaminopyridine, Fmoc-R7R8CH9(NH2)COOH and N,N′-dicyclohexyl-carbodiimide DCC in succession, followed by washing the resultant white solid. 2 See, e.g., “Amino acid ester prodrugs of acyclovir,” Antiviral Chemistry & Chemotherapy, 1992; 3: 157-164
- 3′-esterification may be performed in a similar manner by reacting the 5′-protected hydroxyl compound of formula (IV) dissolved in DMF with 4-dimethylaminopyridine, Fmoc-R7R8CH9(NH2)COOH and N,N′ dicyclohexyl-carbodiimide DCC in succession.
- Preferably, R1 is n-pentyl, X, Y and Z are all O, and R7 and R8 are both methyl.
- It has been found that the compound of the present invention has advantageous pharmacokinetic (PK) properties and improved bioavailability as compared to
Compound 1 of WO 01/83501 A1. The conjugation of a dipeptide moiety to the free amino terminus of the valyl ester of PCT/GB2007/001677 appears not to impair the bioavailability of the compound. Further, it has been found that the compound of the invention exhibits unexpectedly high solubility in water as compared withCompound 1. - Bioavailability is often a key factor in the practical application of a drug as a therapeutic agent and compounds that demonstrate enhanced PK and/or solubility generally have improved potency in vivo over compounds with less favorable PK properties even though their in vitro potency may be similar. Such compounds, i.e., derivatives of known in vitro active compounds, are often referred to as prodrugs.
Novel Compound 7 is an example of such a prodrug. -
Compounds 7 and 9 were tested for antiviral activity as described below and found to be active. In addition, a comparative study of the pharmacokinetic behaviour ofCompounds Compounds Compound 1. - Surprisingly, the water-solubility of
Compound 7 was found to be more than 57-fold greater than the water-solubility ofCompound 1. - For therapeutic use, a pharmaceutically acceptable salt of the compound of the invention may comprise a counter-ion that is pharmaceutically physiologically acceptable. The pharmaceutically or physiologically acceptable acid addition salt forms that the compound of the invention is able to form can conveniently be prepared using the appropriate acids such, for example, as inorganic acids such as hydrohalic acids, e.g., hydrochloride or hydrobromic acid, sulfuric, nitric, phosphoric and the like acids; or organic acids such, for example, as acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfuric, ethanesulfuric, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-amino-salicylic, pamoic and the like acids.
- Conversely, said acid addition salt forms can be converted by treatment with an appropriate base into the free base form.
- The compound of the invention containing an acidic proton may also be converted into its non-toxic metal or amine addition salt by treatment with appropriate organic and inorganic bases. Appropriate base salt forms comprise, for example, the ammonium salts, quaternary ammonium salts, the alkali and earth alkaline metal salts, e.g., the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g., the benzathine, N-methyl, -D-glucamine, hydrabamine salts and bases, and salts with amino acids, such as, for example, arginine, lysine and the like.
- Conversely, said base addition forms can be converted by treatment with an appropriate acid into the free acid form.
- The term “salt” as used herein also comprises the hydrate and solvent addition forms that the compound of the invention is able to form. Examples of such forms are, e.g., hydrates, alcoholate and the like. The term “salt” also comprehends the quaternisation of the nitrogen atoms of the compound. A basic nitrogen can be quaternised with any agent known to those skilled in the art including, for instance, lower alkyl halides, dialkyl sulfates, long chain halides and arylalkyl halides.
- The compound of the invention may also exist in its tautomeric forms. Such forms, although not explicitly indicated in the above formula (III), are intended to be included within the scope of the present invention.
- According to another aspect of the present invention therefore there is provided a compound according to the present invention for use in a method of treatment, particularly the prophylaxis or treatment of a viral infection. In some embodiments, said compound may be provided for use in the treatment or prophylaxis of an infection with the Varicella Zoster virus.
- According to a yet another aspect of the present invention there is provided use of a compound according to the present invention in the manufacture of a medicament for the prophylaxis or treatment of viral infection, especially a viral infection caused by the Varicella Zoster virus, e.g., chicken pox or shingles.
- According to yet another aspect of the present invention there is provided a method of prophylaxis or treatment of viral infection, said method comprising administration to a human or non-human animal patient in need of such treatment an effective amount of a compound according to the present invention.
- According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a compound of the present invention in combination with a pharmaceutically acceptable excipient.
- Medicaments embodying the present invention can be administered by oral, enteral or parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
- For oral administration, compounds embodying the present invention will generally be provided in the form of tablets or capsules, as a powder or granules, or as an aqueous solution or suspension.
- Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
- Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.
- Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- For intramuscular, intraperitoneal, subcutaneous and intravenous use, compounds embodying the present invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Aqueous suspensions embodying the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.
- Compounds embodying the present invention can be presented as liposome formulations.
- In general, a suitable dose will be in the range of 0.001 to 300 mg per kilogram body weight of the recipient per day, preferably in the range of 0.01 to 25 mg per kilogram body weight per day, and most preferably in the range 0.05 to 10 mg per kilogram body weight per day. The desired dose may be presented as two, three, four, five or six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing 0.1 to 1500 mg, preferably 0.2 to 1000 mg, and most preferably 0.5 to 700 mg of active ingredient per unit dosage form.
- In a particularly preferred embodiment, a dose of 100-500 mg of the compound of the present invention may be administered once per day.
- Following is a description by way of example only with reference to the accompanying drawings of embodiments of the present invention.
- In the drawings:
-
FIG. 1 is a graph showing the bioavailability (in arbitrary units) ofCompounds -
FIG. 2 shows the water-solubility ofCompounds -
- Compound 1 (200 mg, 0.5 mmol, prepared as described in WO 01/83501 A1, Example 3, page 15) was dissolved in dry DMF (5 mL), followed by the addition of polymer-bound triphenylphosphine [370 mg, 1.1 mmol, (3 mmol p/g resin)] and di-tert-butyl azodicarboxylate (DBAD) (231 mg, 1.0 mmol) to the mixture and stirred for 20 minutes. A solution of Fmoc-Val-OH (340 mg, 1.0 mmol) in DMF (5 mL) was added dropwise over a period of 30 minutes. The reaction mixture was stirred at room temperature under an argon atmosphere until complete disappearance of the starting material (overnight). The resin was filtered off and washed with ethyl acetate. Piperidine (1 mL, 10 mmol) was added to the solution and stirred for 10 minutes. The solvent was removed under reduced pressure without warming over 35° C. and the residue was dissolved in ethyl acetate (20 mL), washed with 10% NaHCO3 (3×20 mL) and brine (2×20 mL). The final residue was purified by column chromatography (gradient CH2Cl2:
MeOH 100% 98% 95% 90%), to give 137 mg of Compound 5 (55% yield) as a yellow solid. - 1H-NMR (CDCl3) δ: 8.3 (1H, s), 7.55 (2H, d), 7.15 (2H, d), 6.6 (1H, s), 6.25 (1H, t), 4.45-4.30 (4H, m), 3.23 (1H, d), 2.80 (1H, m), 2.53 (2H, t), 2.12 (1H, m), 1.97 (1H, m), 1.60 (2H, m), 1.24 (4H, m), 0.90-0.78 (9H, m).
- 13C-NMR (CDCl3) δ: 175.16, 171.62, 156.26, 154.89, 145.19, 135.29, 129.02, 125.69, 124.95, 108.60, 96.82, 88.73, 85.08, 70.90, 64.19, 60.19, 41.91, 35.82, 32.32, 31.44, 30.89, 22.50, 19.30, 17.24, 13.99.
-
- A solution of
Compound 5 prepared as described above in Description 1 (95 mg, 0.19 mmol) in dichloromethane (5 mL) was successively treated with the commercially available amino-protected dipeptide Fmoc-Val-Pro-OH (100 mg, 0.23 mmol), (benzotriazol-1-yl-oxy)-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP) (101 mg, 0.23 mmol) and triethylamine (0.032 mL, 0.23 mmol). The reaction mixture was stirred at room temperature for 15 hours and the solvent was evaporated to dryness. The residue was dissolved in ethyl acetate 26 (50 mL), washed with 10% aqueous citric acid (3×20 mL), 10% aqueous NaHCO3 (3×20 mL), water (3×20 mL) and brine (3×20 mL). The organic layer was dried (Na2SO4), filtered and evaporated to dryness. The final residue was purified by CCTLC on the Chromatotron (dichloromethane-methanol, 25:1) to give the protected derivative Fmoc-Compound 7 (130 mg, 74%) as a white amorphous solid. - 1H NMR (300 MHz, acetone-d6) δ: 0.84-1.04 (m, 15H, 2γ-CH3, Val1 y Val2, CH3), 1.20-1.41 (m, 4H, CH2), 1.62 (m, 2H, CH2), 1.91-2.18 (m, 6H, β-CH, Val1 y Val2, β-CH2, Pro, γ-CH2, Pro), 2.37 (m, 1H, H-2′a), 2.62-2.70 (m, 3H, H-2′b, CH2), 3.69-3.84 (m, 2H, δ-CH2, Pro), 4.22-4.72 (m, 11H, CH2, Fmoc, CH, Fmoc, 2H-5′, H-4′, H-3′, 2α-CH, Val1 y Val2, α-CH, Pro, OH), 6.30 (t, 1H, H-1′, J=5.9 Hz), 6.44 (d, 1H, NH, Val1, J=8.5 Hz), 7.22 (s, 1H, H-5), 7.35 y 7.81 (AA′BB′ system, 4H, Ar, J=8.5 Hz), 7.30-7.89 (m, 9H, Ar, Fmoc, NH, Val2), 8.73 (s, 1H, H-4).
- 13C NMR (100 MHz, acetone-d6) δ: 13.6 (CH3), 17.7, 18.1, 18.7, 19.1 (4C-γ, Val1 y Val2), 22.5, 25.1, 28.4, 30.8, 31.1, 31.2 (4CH2, C-β, Pro, C-γ, Pro), 31.5, 35.7 (2C-β, Val1 y Val2), 41.8 (C-2′), 47.4, 47.7 (C-δ, Pro, CH Fmoc), 58.1, 58.6 (C-α, Val2, C-α, Pro), 59.9 (C-α, Val1), 64.1 (C-5′), 66.6 (CH2, Fmoc), 70.5 (C-3′), 85.3, 88.5 (C-1′, C-4′), 99.0 (C-5), 107.7 (C-4a), 120.1, 125.0, 125.1, 125.6, 127.3, 127.9 (4C—Ar, Fmoc, C-Hb, ipso-C), 129.2 (C-Ha), 137.1 (C-4), 141.4 (C—Ar, Fmoc), 144.4, 144.6 (para-C, C—Ar, Fmoc), 154.3, 154.7 (C-6, C═O, Fmoc), 156.5 (C-2), 171.6, 171.7, 172.0, 172.1 (C═O, Val1, C═O, Val2, C═O, Pro, C-7a).
- MS (ESI+): m/z 916.3 (M+1)+, 938.0 (M+Na)+. Elemental analysis calcd (%) for C52H61N5O10: C, 68.18; H, 6.71; N, 7.65; found: C, 68.01; H, 6.95; N, 7.79.
-
- To a solution of Fmoc-
Compound 7 prepared as described in Example 1 above (120 mg, 0.13 mmol) in DMF (3 ml) piperidine (0.15 ml, 1.5 mmol) was added and the mixture was stirred for 10 minute. The solvent was removed under reduced pressure and the residue was purified by CCTLC on the Chromatotron (ethyl acetate-methanol, 10:1) to give the deprotected derivative Compound 7 (81 mg, 89%) as a white foam. - 1H NMR (300 MHz, acetone-d6) δ: 0.78-0.97 (m, 15H, 2γ-CH3, Val1 y Val2, CH3), 1.17-1.41 (m, 4H, CH2), 1.65 (m, 2H, CH2), 1.83-2.35 (m, 7H, 2β-CH, Val1 y Val2, β-CH2, Pro, γ-CH2, Pro, H-2′a), 2.59-2.70 (m, 3H, H-2′b, CH2), 3.51-3.78 (m, 2H, δ-CH2, Pro), 3.93 (d, 1H, α-CH, Val1, J=8.1 Hz), 4.32-4.58 (m, 7H, 2H-5′, H-4′, H-3′, α-CH, Val2, α-CH, Pro, OH), 6.31 (t, 1H, H-1′, J=5.8 Hz), 7.25 (s, 1H, H-5), 7.33 (AA′BB′ system, 2H, Ar, J=8.5 Hz), 7.75-7.86 (m, 3H, Ar, NH, Val2), 8.71 (s, 1H, H-4).
- 13C NMR (100 MHz, acetone-d6) δ: 13.9 (CH3), 18.4, 19.0, 19.1, 19.6 (4C-γ, Val1 y Val2), 22.8, 25.4, 28.2, 31.0, 31.4, 31.8 (4CH2, C-β, Pro, C-γ, Pro), 32.5, 35.9 (2C-β, Val1 y Val2), 42.0 (C-2′), 47.6 (C-δ, Pro), 58.8 (C-α, Val2), 60.1, 60.4 (C-α, Val1, C-α, Pro), 64.4 (C-5′), 70.8 (C-3′), 85.6, 88.8 (C-1′, C-4′), 99.4 (C-5), 108.2 (C-4a), 125.3 (C-Hb), 127.1 (ipso-C), 129.5 (C-Ha), 137.5 (C-4), 144.9 (para-C), 154.8 (C-6), 155.1 (C-2), 168.9, 172.0, 172.3, 172.7 (C═O, Val1, C═O, Val2, C═O, Pro, C-7a).
- MS (ESI+): m/z 694.3 (M+1)+, 716.5 (M+Na)+, 1387.7 (2M+1)+, 1409.6 (2M+Na)+. Elemental analysis calcd. (%) for C37H53N5O7: C, 65.37; H, 7.86; N, 10.30; found: C, 65.26; H, 8.01; N, 10.49.
-
- To a solution of Compound 1 (200 mg, 0.5 mmol) in dry pyridine (4 ml), tert-butyldimethylsilyl chloride (302 mg, 2.0 mmol) was added. The reaction mixture was stirred at room temperature under an argon atmosphere for 48 hours. The solvent was removed under reduced pressure. The residue (5′-silyl derivative) was dissolved in DMF (3 ml) and 4-dimethylaminopyridine (12 mg, 0.1 mmol), Fmoc-Val-OH (225 mg, 0.66 mmol) and N,N′-dicyclohexyl-carbodiimide (137 mg, 0.66 mmol) were successively added at 0° C. The reaction mixture was stirred at room temperature for 2 hours. The white solid was filtered, washed with DMF and the solvent was evaporated to dryness. The residue, thus obtained, was dissolved in ethyl acetate (50 mL), washed with 10% aqueous citric acid (3×20 mL), 10% aqueous NaHCO3 (3×20 mL), water (3×20 mL) and brine (3×20 mL). The organic layer was dried (Na2SO4), filtered and evaporated to dryness. The final residue was purified by flash column chromatography on silica gel (dichloromethane/methanol, 40:1) to give 230 mg (83%) of Fmoc-Compound 8 as a white foam.
- 1H NMR (300 MHz, acetone-d6): δ 0.14 (s, 3H, CH3, Si—CH3), 0.16 (s, 3H, CH3, Si—CH3), 0.89 (m, 12H, tBu, CH3), 1.02 (d, 6H, γ-CH3, Val), 1.27-1.40 (m, 4H, 2CH2), 1.63 (m, 2H, CH2), 1.81 (m, 1H, β-CH, Val), 2.21-2.39 (m, 2H, 2H-2′), 2.66 (t, 2H, CH2, J=7.3 Hz), 4.02 (m, 2H, 2H-5′), 4.17-4.40 (m, 5H, CH2, Fmoc, CH, Fmoc, H-4′, α-CH, Val), 5.40 (m, 1H, H-3′), 6.31 (t, 1H, H-1′, J=5.9 Hz), 6.98 (d, 1H, NH, J=8.8 Hz), 7.03 (s, 1H, H-5), 7.29-7.86 (m, 8H, Ar Fmoc), 7.33 y 7.74 (AA′BB′ system, 4H, Ar, J=8.1 Hz), 8.68 (s, 1H, H-4).
- MS (ESI+): m/z 834.3 (M+1+).
- Elemental analysis: calcd (%) for C48H61N3O8Si: C, 68.95; H, 7.35; N, 5.03; found: C, 69.07; H, 7.49; N, 5.58.
-
- To a solution of Fmoc-Compound 8 (179 mg, 0.22 mmol) in DMF (5 ml), piperidine (0.25 ml, 2.5 mmol) was added and the mixture was stirred for 5 minutes. The solvent was evaporated to dryness. The residue was purified by CCTLC on the Chromatotron (dichloromethane/methanol, 20:1) to afford 122 mg (93%) of Compound 8 as a yellow foam.
- 1H NMR (300 MHz, acetone-d6): δ 0.16 (s, 3H, CH3, Si—CH3), 0.18 (s, 3H, CH3, Si—CH3), 0.87-0.99 (m, 18H, tBu, γ-CH3, Val, CH3), 1.29-1.40 (m, 4H, 2CH2), 1.66 (m, 2H, CH2), 2.03 (m, 1H, β-CH, Val), 2.22-2.37 (m, 2H, 2H-2′), 2.67 (t, 2H, CH2, J=7.5 Hz), 3.92 (d, 1H, α-CH, Val, J=6.8 Hz), 4.05 (m, 2H, 2H-5′), 4.33 (m, 1H, H-4′), 5.37 (m, 1H, H-3′), 6.29 (m, 1H, H-1′), 7.03 (s, 1H, H-5), 7.34 y 7.75 (AA′BB′ system, 4H, Ar, J=8.1 Hz), 8.70 (s, 1H, H-4).
- MS (ESI+): m/z 612.4 (M+1+).
- Elemental analysis: calcd (%) for C33H51N3O6Si: C, 64.57; H, 8.37; N, 6.85; found: C, 64.44; H, 8.51; N, 6.89.
-
- Following the method described in Example 1 for the synthesis of Fmoc-
compound 7, a solution of Compound 8 (81 mg, 0.13 mmol) in dichloromethane (2 ml) was successively reacted with Fmoc-Val-Pro-OH (69 mg, 0.16 mmol), BOP (70 mg, 0.16 mmol) and triethylamine (0.022 ml, 0.16 mmol) for 15 hours. After the work-up the final residue was by CCTLC on the Chromatotron (dichloromethane/methanol, 50:1) to afford 109 mg (80%) of Fmoc-Compound 9 as a white foam. - 1H NMR (300 MHz, acetone-d6): δ 0.16 (s, 3H, CH3, Si—CH3), 0.18 (s, 3H, CH3, Si—CH3), 0.86-1.05 (m, 24H, tBu, 2γ-CH3, Val1, Val2, CH3), 1.30-1.36 (m, 4H, 2CH2), 1.64 (m, 2H, CH2), 1.96-2.38 (m, 8H, 2β-CH, Val1, Val2, β-CH2, Pro, γ-CH2, Pro, 2H-2′), 2.66 (t, 2H, CH2, J=7.3 Hz), 3.63-3.82 (m, 2H, δ-CH2, Pro), 4.06 (m, 2H, 2H-5′), 4.21-4.38 (m, 6H, CH2, Fmoc, CH, Fmoc, 2α-CH Val1, Val2, α-CH, Pro), 4.61 (m, 1H, H-4′), 5.40 (m, 1H, H-3′), 6.45 (m, 1H, H-1′), 6.66 (d, 1H, NH, Val1, J=8.3 Hz), 7.03 (s, 1H, H-5), 7.28-7.86 (m, 9H, Ar, Fmoc, NH Val2), 7.34 y 7.75 (AA′BB′ system, 4H, Ar, J=8.1 Hz), 8.71 (s, 1H, H-4).
- MS (ESI+): m/z 1030.3 (M+1+).
- Elemental analysis: calcd (%) for C58H77N5O10Si: C, 67.48; H, 7.52; N, 6.78; found: C, 67.63; H, 7.59; N, 6.81.
-
- According to the deprotection method described for Compound 3 (See Example 7 below), a solution of Fmoc-Compound 9 (109 mg, 0.11 mmol) in MeOH (2 ml) was reacted with HCl 0.1N in MeOH (1.1 ml, 0.11 mmol) for 3 hours. The residue obtained after the work-up, was dissolved in DMF (2 mL) and piperidine was added. After 5 minutes at room temperature the solvent was evaporated to dryness. The final residue was purified by CCTLC on the Chromatotron (dichloromethane/methanol, 50:1) to afford 40 mg (52%) of the fully deprotected Compound 9 as a yellow foam.
- 1H NMR (300 MHz, acetone-d6): δ 0.83-1.02 (m, ISH, 2γ-CH3, Val1, Val2, CH3), 1.29-1.39 (m, 4H, 2CH2), 1.65 (m, 2H, CH2), 1.88-2.48 (m, 8H, 2β-CH, Val1, Val2, β-CH2, Pro, γ-CH2, Pro, 2H-2′), 2.66 (t, 2H, CH2, J=7.5 Hz), 3.53-3.76 (m, 3H, α-CH, Val1, δ-CH2, Pro), 3.93-4.55 (m, 6H, 2H-5′, H-4′, α-CH, Val2, α-CH, Pro, OH), 5.43 (m, 1H, H-3′), 6.37 (m, 1H, H-1′), 7.05 (s, 1H, H-5), 7.34 y 7.74 (AA′BB′ system, 4H, Ar, J=8.5 Hz), 7.69 (d, 1H, NH, Val2, J=7.9 Hz), 8.86 (s, 1H, H-4).
- MS (ESI+): m/z 694.3 (M+1+).
- Elemental analysis: calcd (%) for C37H53N5O8: C, 63.86; H, 7.68; N, 10.06; found: C, 64.01; H, 7.54; N, 10.21.
- If desired, Fmoc-Compound 8 may be fully deprotected to form Compound 3 of PCT/GB2007/00167.
- Fmoc-Compound 8 (128 mg, 0.15 mmol) was dissolved in MeOH (1 ml) and a solution of HCl 0.1N in MeOH (1.85 ml, 0.19 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours and the solvent was evaporated to dryness. The residue was dissolved in dichloromethane (40 mL) and washed with a 10% aqueous NaHCO3 (3×20 mL).
- The organic layer was dried, filtered and evaporated to dryness. The residue was dissolved in DMF (3 mL), piperidine (0.15 ml, 1.5 mmol) was added and stirred at room temperature for 5 minutes. The solvent was removed under reduced pressure and the residue was purified by CCTLC on the Chromatotron (dichloromethane/methanol, 20:1) to yield 58 mg (76%) of fully deprotected Compound 3 as a yellow oil.
- 1H NMR (300 MHz, DMSO-d6): δ 0.80-0.91 (m, 9H, γ-CH3, Val, CH3), 1.28 (m, 4H, 2CH2), 1.58 (m, 2H, CH2), 1.87 (m, 1H, β-CH, Val), 2.30 (m, 1H, H-2′a), 2.55-2.72 (m, 3H, CH2, H-2′b), 3.17-3.73 (m, 3H, 2H-5′, α-CH, Val), 4.15 (m, 1H, H-4′), 5.25 (m, 1H, H-3′), 5.32 (t, 1H, 5′-OH, J=5.2 Hz), 6.22 (t, 1H, H-1′, J=6.1 Hz), 7.21 (s, 1H, H-5), 7.31 y 7.72 (AA′BB′ system, 4H, Ar, J=8.3 Hz), 8.78 (s, 1H, H-4).
- MS (ESI+): m/z 498.3 (M+1+).
-
- To a solution of Compound 1 (188 mg, 0.47 mmol) in DMF (4 mL) at 0° C., 4-dimethylaminopyridine (17 mg, 0.14 mmol), Fmoc-Val-OH (481 mg, 1.42 mmol) and N,N′-dicyclohexyl-carbodiimide DCC (292 mg, 1.42 mmol) were successively added. The reaction mixture was stirred at room temperature for 15 hours. The white solid was filtered, washed with DMF and the solvent was evaporated to dryness. The residue, thus obtained, was dissolved in ethyl acetate (40 mL), washed with 10% aqueous citric acid (3×20 mL), 10% aqueous NaHCO3 (3×20 mL), water (3×20 mL) and brine (3×20 mL). The organic layer was dried (Na2SO4), filtered and evaporated to dryness. The final residue was purified by flash column chromatography on silica gel (hexane/ethyl acetate, 3:1) to give 343 mg (70%) of Fmoc-Compound 10 as a white foam.
- 1H NMR (400 MHz, acetone-d6): δ 0.88 (t, 3H, CH3, J=6.9 Hz), 0.91-1.02 (m, 12H, 2γ-CH3, Val-3′, Val-5′), 1.30-1.34 (m, 4H, 2CH2), 1.57-1.64 (m, 2H, CH2), 2.14-2.27 (m, 2H, β-CH, Val-3′, Val-5′), 2.48 (m, 1H, H-2′a), 2.61 (t, 2H, CH2, J=7.8 Hz), 2.78-2.82 (m, 1H, H-2′b), 4.18-4.61 (m, 11H, 2CH2, Fmoc-3′, Fmoc-5′, 2CH, Fmoc-3′, Fmoc-5′, 2H-5′, H-4′, 2α-CH, Val-3′, Val-5′), 5.45 (m, 1H, H-3′), 6.33 (t. IH, H-1′, J=5.9 Hz), 6.97-7.03 (m, 2H, NH, Val-3′, Val-5′), 7.07 (s, 1H, H-5), 7.24-7.85 (m, 16H, Ar, Fmoc), 7.19 y 7.58 (AA′BB′ system, 2H, Ar, J=8.2 Hz), 8.54 (s, 1H, H-4).
- MS (ESI+): m/z 1041.3 (M+1+).
- Elemental analysis: calcd (%) for C62H66N4O11: C, 71.38; H, 6.38; N, 5.37; found: C, 71.12; H, 6.51; N, 5.50.
-
- To a solution of Fmoc-Compound 10 (330 mg, 0.32 mmol) in DMF (12 ml) piperidine (0.6 ml, 6.0 mmol) was added and the mixture was stirred for 5 minutes. The solvent was evaporated to dryness. The residue was purified by CCTLC on the Chromatotron (dichloromethane/methanol, 20:1) to afford 181 mg (95%) of Compound 10 as a yellow oil.
- 1H NMR (300 MHz, acetone-d6): δ 0.81-0.99 (m, 15H, 2γ-CH3, Val-3′, Val-5′, CH3), 1.29-1.36 (m, 4H, 2CH2), 1.62-1.67 (m, 2H, CH2), 1.91-2.07 (m, 3H, 2β-CH, Val-3′, Val-5′, H-2′a), 2.44 (m, 1H, H-2′b), 2.67 (t, 2H, CH2, J=8.1 Hz), 4.31-4.50 (m, 5H, 2H-5′, H-4′, 2α-CH, Val-3′, Val-5′), 5.38 (m, 1H, H-3′), 6.32 (t, 1H, H-1′, J=6.2 Hz), 7.07 (s, 1H, H-5), 7.34 y 7.74 (AA′BB′ system, 4H, Ar, J=8.3 Hz), 8.65 (s, 1H, H-4).
- MS (ESI+): m/z 597.3 (M+1+), 1193.7 (2M+1+).
-
- Following the method described in Example 1 for the synthesis of Fmoc-
compound 7, a solution of compound 10 (113 mg, 0.19 mmol) in dichloromethane (5 ml) was successively reacted with Fmoc-Val-Pro-OH (198 mg, 0.45 mmol), BOP (201 mg, 0.45 mmol) and triethylamine (0.063 ml, 0.45 mmol). After the work-up the final residue was by CCTLC on the Chromatotron (dichloromethane/methanol, 40:1) to afford 184 mg (68%) of Fmoc-compound 11 as a yellow oil. - 1H NMR (300 MHz, acetone-d6): δ 0.86-1.05 [m, 27H, 4γ-CH3, (Val1, Val2)-3′ y (Val1, Val2)-5′, CH3], 1.30 (m, 4H, 2CH2), 1.62 (m, 2H, CH2), 1.91-2.55 [m, 14H, 2H-2′, 4β-CH, (Val1, Val2)-3′ and (Val1, Val2)-5′, 2β-CH2, Pro-3′, Pro-5′, 2y-CH2, Pro-3′, Pro-5′], 2.64 (m, 2H, CH2), 3.58-3.84 (m, 4H, 2δ-CH2, Pro-3′, Pro-5′), 4.24-4.60 (m, 15H, 2CH2, Fmoc-3′, Fmoc-5′, 2CH, Fmoc-3′, Fmoc-5′, 2H-5′, H-4′, 4α-CH, (Val1, Val2)-3′ and (Val1, Val2)-5′, 2α-CH Pro-3′, Pro-5′), 5.46 (m, 1H, H-3′), 6.65 (m, 1H, H-1′), 7.19 (s, 1H, H-5), 7.33-7.88 (m, 16H, Ar Fmoc), 7.34 y 7.86 (AA′BB′ system, 4H, Ar, J=7.5 Hz), 8.70 (s, 1H, H-4).
- MS (ESI+): m/z 1434.4 (M+1+).
-
- To a solution of Fmoc-compound 11 (164 mg, 0.11 mmol) in DMF (12 ml), piperidine (0.25 ml, 2.5 mmol) was added and the mixture was stirred for 5 minutes. The solvent was evaporated to dryness. The residue was purified by CCTLC on the Chromatotron (dichloromethane/methanol, 10:1) to afford 98 mg (87%) of compound 11 as a yellow foam.
- 1H NMR (300 MHz, acetone-d6): δ 0.88-1.02 [m, 27H, 4γ-CH3, (Val1, Val2)-3′, (Val1, Val2)-5′, CH3], 1.29-1.40 (m, 4H, 2CH2), 1.6S (m, 2H, CH2), 1.72-2.57 [m, 14H, 2H-2′, 4β-CH, (Val1, Val2)-3′, (Val1, Val2)-5′, 2β-CH2, Pro-3′, Pro-5′, 2γ-CH2, Pro-3′, Pro-5′], 2.67 (t, 2H, CH2, J=7.7 Hz), 3.60-4.58 (m, 13H, 2H-5′, H-4′, 4α-CH, (Val1, Val2)-3′, (Val1, Val2)-5′, 2α-CH Pro-3′, Pro-5′, 2δ-CH2, Pro-3′, Pro-5′), 5.45 (m, 1H, H-3′), 6.35 (m, 1H, H-1′), 7.20 (s, 1H, H-5), 7.34 y 7.70 (AA′BB′ system, 2H, Ar, J=8.1 Hz), 7.75-7.89 (m, 2H, 2NH Val2-3′, Val2-5′), 8.68 (s, 1H, H-4).
- MS (ESI+): m/z 989.5 (M+1+).
- Elemental analysis: calcd (%) for C52H76N8O11: C, 63.14; H, 7.74; N, 11.33; found: C, 63.27; H, 7.69; N, 11.50.
- A study was conducted with
Compounds Compound 1 after oral dosing in mice. Three groups of female mice received equimolar doses of Compound 1 (25 mg/kg), 5 (31.25 mg/kg; equivalent to 25 mg/kg of Compound 1) or 7 (41.8 mg/kg; equivalent to 25 mg/kg of compound 1) as a single oral gavage dose formulated in 0.5% carboxymethylcellulose. The mice were serially sacrificed at time-points ranging from 0.25 to 3 hours post dosing (3 mice/time-point), and plasma samples were taken and analyzed forCompound 1 concentration using a non-validated HPLC method with fluorescence detection. Results are reported as relative peak areas forCompound 1, which assumes that peak area is directly proportional to concentration over these ranges of concentrations. - The results of this study are shown in Table 1 below and in
FIG. 1 of the accompanying drawings. Plasma concentrations ofCompound 1 were much higher inmice receiving Compounds mice receiving Compound 1. Note that although these data do not provide absolute plasma concentrations ofCompound 1, one can estimate from the peak areas thatCompound 5 increases the oral bioavailability ofCompound 1 by approximately 8-fold andCompound 7 by approximately 12-fold (as estimated by the AUC values). - In conclusion, this data supports the hypothesis that
Compound 7 according to the present invention is a prodrug ofCompound 1, and greatly increases the oral bioavailability ofCompound 1. -
TABLE 1 Time (min) after Compound 1 in plasma (area under the curve (HPLC))oral gavage Compound 7 Compound 5Compound 115 32 18 2.6 30 52 19 2.9 45 87 39 4.0 60 44 42 4.2 120 14 28 2.5 180 6.2 8.1 3.4 In all cases, only Compound 1 was detected in plasma.Compound 5 was markedly more bioavailable thanCompound 1.Compound 7 was more bioavailable thanCompound 5. - A variety of test compounds have been evaluated for their substrate activity against purified CD26, human serum (HS), and bovine serum (BS) in Eppendorf tubes. The 400 μL reaction mixture contained 50 μM of test compound in PBS (containing 0.1% DMSO). The reaction was started by the addition of purified CD26 (1.5 mU) or 20% of HS (in PBS) or BS (in PBS) at 37° C. At different time points, 100 μL was withdrawn from the reaction mixture, added to 200 μL methanol, and put on ice for ˜10 min. Then, the mixture was centrifuged at 13,000 rpm for 5 min at 4° C. and 250 μL of supernatant was analyzed by HPLC on a reverse phase RP-8 column, using following gradients:
- Gradient A (Buffer A: 50 mM NaH2PO4+5 mM heptane-sulfonic acid pH 3.2; buffer B: acetonitrile): 2 min 98% A+2% B; 6 min linear gradient to 80% A+20% B; 2 min linear gradient to 75% A+25% B; 2 min linear gradient to 65% A+35% B; 18 min linear gradient to 50% A+50% B; 5
min 50% A+50% B; 5 min linear gradient to 98% A+2% B; 5 min equilibration at 98% A+2% B. - Gradient B: 2 min 98% A+2% B; 6 min linear gradient to 80% A+20% B; 2 min linear gradient to 75% A+25% B; 2 min linear gradient to 65% A+35% B; 8 min linear gradient to 50% A+50% B; 10
min 50% A+50% B; 10 min linear gradient to 20% A+80% B; 5min 20% A+80% B; 15 min linear gradient to 98% A+2% B; 5 min 98% A+2% B. -
TABLE 2 Conversion of Compound 7 toCompound 5 and Compound 1 in vitroFormation of hydrolysis products (%) Time (hr) Compound 7Compound 5Compound 1CD26 0 100 0 0 2 0 50.6 49.4 6 0 37.1 62.9 20 0 24.5 75.5 Bovine serum 0 100 0 0 10% 1 59.8 19.9 20.3 4 20.4 34.7 44.8 20 3.3 21 74.4 Human serum 0 100 0 0 10% 1 31 11.4 57.6 4 5.0 21.5 73.4 20 1.8 9.7 88.5 Rapid conversion of Compound 7 toCompound 5 occurs in the presence of purified CD26 (1.5 mU in PBS), bovine serum (10%) and human serum (10%) in PBS.Compound 7 is fully stable in PBS for 6 hrs at 37° C. (not shown).Compound 5 is unstable. It spontaneously degrades toCompound 1 in buffer.Compound 5 is stabilized as a salt derivative. - The objective of this study was to compare the antiviral activity of
Compounds Compounds - VZV-drug susceptibility assays were performed on confluent HEL cells in 96-well microtiter plates. Monolayers were infected with 20 PFU of cell-associated virus per well. For each assay, virus controls (infected-untreated cells) were included. After a 2-hour incubation period, the virus inoculum was removed and the media replaced by the different dilutions (in duplicate) of the tested molecules. Serial dilutions of test compounds were incubated with the infected monolayers for 5 days. After the 5-day incubation period, the cells were fixed and stained with Giemsa, and the level of virus-induced cytopathic effect was determined by counting the number of plaques for each dilution. Activity was expressed as EC50 (effective compound concentration required to reduce virus-plaque formation by 50%) compared to the untreated control.
-
TABLE 3 EC50 a (μM) VZV TK+ VZV TK− Cmpd YS OKA 07/1 MCC (μM) CC50(μM) 5 0.03 0.014 >1 >1 >0.5 7 0.01 0.012 >1 >1 >0.5 1 0.02 0.008 >1 >1 >5.0 a50% effective concentration -
TABLE 3b EC50 a (μM) VZV TK+ VZV TK− Cmpd YS OKA 07/1 MCC (μM) CC50(μM) 3 0.004 0.007 >5 20 >5 9 0.016 0.017 >5 20 >5 1 0.003 0.003 >20 >20 >5 a50% effective concentration -
Compounds - The water-solubility of
Compound 7 was determined by HPLC analysis and compared with that ofCompound 5 andparent Compound 1. HPLC was carried out on a Waters 484 System using Novapack C18 reverse phase column. Flow rate: 1 mL/min. Detection: UV 254 nm. Gradient solvent system AlB (acetonitrile/water): initial 15% A+85% B; 5 min linear gradient to 25% A+75% B; 5 min linear gradient to 35% A+65% B; 10 min linear gradient to 45% A+55% B; 5 min linear gradient to 60% A+40% B and 5 min linear gradient to 100% A. - Excess amount of the prodrug or the parent drug was suspended in deionised water, sonicated for 10 min at room temperature, and then equilibrated overnight at room temperature. The samples were centrifuged at 14.000 rpm in an Eppendorf microcentrifuge for 1.5 min at room temperature. An aliquot of the clear supernatant was removed and diluted to a concentration within the range of a five-point standard curve. Water-solubility was calculated from each peak area of the above solution by HPLC compared with the sample dissolved in acetonitrile, the concentration of which is already known.
- The values of solubility and partition coefficients of the prodrugs and parent compound are provided in Table 4 below. Predicted partition coefficient values suggest that lipophilicity can be significantly reduced from 3.24 to 1.60 or 0.70 upon introduction of the valyl or tripeptidyl moiety. The prodrugs exhibited higher water-solubility than the parent drug as shown in
FIG. 2 .Compound 7 prodrug improved the water-solubility (1.27 mg/mL) more than 57-fold in comparison with the parent Compound 1 (0.022 mg/mL). This result suggests that the CD26 prodrug approach could be useful for increasing the water-solubility of hydrophobic drugs. -
TABLE 4 Physicochemical properties of Compounds Test Solubility in water Compound Predicted logPa Predicted logWa (mg/ml)b 1 3.24 −1.97 0.022 ± 0.007 5 1.60 −4.49 0.211 ± 0.044 7 0.70 −7.83 1.27 ± 0.05 aPredicted value of logP and logW (water solubility) was obtained using the website http://www.logp.com bData are means of three determinations
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/547,988 US20150080318A1 (en) | 2007-09-07 | 2014-11-19 | Compositions for the Treatment or Prophylaxis of Viral Infections |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0717526.8 | 2007-09-07 | ||
GB0717526A GB2452556A (en) | 2007-09-07 | 2007-09-07 | Nucleoside analogues esterified at 3 and/or 5 positions by neutral non-polar amino acid, or oligopeptide thereof, for combating Varicella Zoster virus |
PCT/EP2008/007009 WO2009030410A1 (en) | 2007-09-07 | 2008-08-27 | Improvements in or relating to compositions for the treatment or prophylaxis of viral infections |
US67639410A | 2010-06-08 | 2010-06-08 | |
US13/971,631 US8912163B2 (en) | 2007-09-07 | 2013-08-20 | Compositions for the treatment or prophylaxis of viral infections |
US14/547,988 US20150080318A1 (en) | 2007-09-07 | 2014-11-19 | Compositions for the Treatment or Prophylaxis of Viral Infections |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/971,631 Continuation US8912163B2 (en) | 2007-09-07 | 2013-08-20 | Compositions for the treatment or prophylaxis of viral infections |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150080318A1 true US20150080318A1 (en) | 2015-03-19 |
Family
ID=38640477
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/676,394 Expired - Fee Related US8513215B2 (en) | 2007-09-07 | 2008-08-27 | Compositions for the treatment or prophylaxis of viral infections |
US13/971,631 Expired - Fee Related US8912163B2 (en) | 2007-09-07 | 2013-08-20 | Compositions for the treatment or prophylaxis of viral infections |
US14/547,988 Abandoned US20150080318A1 (en) | 2007-09-07 | 2014-11-19 | Compositions for the Treatment or Prophylaxis of Viral Infections |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/676,394 Expired - Fee Related US8513215B2 (en) | 2007-09-07 | 2008-08-27 | Compositions for the treatment or prophylaxis of viral infections |
US13/971,631 Expired - Fee Related US8912163B2 (en) | 2007-09-07 | 2013-08-20 | Compositions for the treatment or prophylaxis of viral infections |
Country Status (4)
Country | Link |
---|---|
US (3) | US8513215B2 (en) |
GB (1) | GB2452556A (en) |
TW (1) | TW200927147A (en) |
WO (1) | WO2009030410A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140011764A1 (en) * | 2000-04-17 | 2014-01-09 | University College Cardiff Consultants Limited | Anti-Viral Pyrimidine Nucleoside Analogues |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2452556A (en) * | 2007-09-07 | 2009-03-11 | Univ Leuven Kath | Nucleoside analogues esterified at 3 and/or 5 positions by neutral non-polar amino acid, or oligopeptide thereof, for combating Varicella Zoster virus |
EP2625181B1 (en) * | 2010-10-09 | 2016-07-13 | ContraVir Pharmaceuticals, Inc. | Method of preparation of antiviral compounds and useful intermediates thereof |
CN102443032B (en) * | 2010-10-09 | 2015-07-22 | 英希比泰克斯公司 | Method for preparation of antiviral composition and application of intermediate thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007129083A1 (en) * | 2006-05-09 | 2007-11-15 | University College Cardiff Consultants Limited | Anti-viral pyrimidine nucleoside derivatives |
US7585851B2 (en) * | 2000-06-15 | 2009-09-08 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
US7820631B2 (en) * | 2000-04-17 | 2010-10-26 | Rega Foundation | Anti-viral pyrimidine nucleoside analogues |
US8513215B2 (en) * | 2007-09-07 | 2013-08-20 | Katholieke Universiteit Leuven | Compositions for the treatment or prophylaxis of viral infections |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5783689A (en) * | 1996-11-12 | 1998-07-21 | University Of Notre Dame | Antibacterial and antifungal nucleosides |
-
2007
- 2007-09-07 GB GB0717526A patent/GB2452556A/en not_active Withdrawn
-
2008
- 2008-08-27 WO PCT/EP2008/007009 patent/WO2009030410A1/en active Application Filing
- 2008-08-27 US US12/676,394 patent/US8513215B2/en not_active Expired - Fee Related
- 2008-09-05 TW TW097134247A patent/TW200927147A/en unknown
-
2013
- 2013-08-20 US US13/971,631 patent/US8912163B2/en not_active Expired - Fee Related
-
2014
- 2014-11-19 US US14/547,988 patent/US20150080318A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7820631B2 (en) * | 2000-04-17 | 2010-10-26 | Rega Foundation | Anti-viral pyrimidine nucleoside analogues |
US8551965B2 (en) * | 2000-04-17 | 2013-10-08 | University College Cardiff Consultants Limited | Anti-viral pyrimidine nucleoside analogues |
US7585851B2 (en) * | 2000-06-15 | 2009-09-08 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
WO2007129083A1 (en) * | 2006-05-09 | 2007-11-15 | University College Cardiff Consultants Limited | Anti-viral pyrimidine nucleoside derivatives |
US8329664B2 (en) * | 2006-05-09 | 2012-12-11 | University College Cardiff Consultants Limited | Anti-viral pyrimidine nucleoside derivatives |
US8859512B2 (en) * | 2006-05-09 | 2014-10-14 | University College Cardiff Consultants Limited | Anti-viral pyrimidine nucleoside derivatives |
US8513215B2 (en) * | 2007-09-07 | 2013-08-20 | Katholieke Universiteit Leuven | Compositions for the treatment or prophylaxis of viral infections |
US8912163B2 (en) * | 2007-09-07 | 2014-12-16 | Katholieke Universiteit Leuven | Compositions for the treatment or prophylaxis of viral infections |
Non-Patent Citations (1)
Title |
---|
Angell et al, Bioorganic & Medicinal Chemistry Letters, 2004, 14, 2397-2399. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140011764A1 (en) * | 2000-04-17 | 2014-01-09 | University College Cardiff Consultants Limited | Anti-Viral Pyrimidine Nucleoside Analogues |
US9351970B2 (en) * | 2000-04-17 | 2016-05-31 | Rega Foundation | Anti-viral pyrimidine nucleoside analogues |
Also Published As
Publication number | Publication date |
---|---|
US20130338096A1 (en) | 2013-12-19 |
US8912163B2 (en) | 2014-12-16 |
GB2452556A (en) | 2009-03-11 |
US20100256087A1 (en) | 2010-10-07 |
GB0717526D0 (en) | 2007-10-17 |
WO2009030410A1 (en) | 2009-03-12 |
US8513215B2 (en) | 2013-08-20 |
TW200927147A (en) | 2009-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7951787B2 (en) | Phosphoramidate compounds and methods of use | |
EP1948242B1 (en) | Cytotoxic compounds | |
US20150080318A1 (en) | Compositions for the Treatment or Prophylaxis of Viral Infections | |
WO2007112348A2 (en) | Prodrug composition | |
EP1543019A2 (en) | Modified pna molecules | |
US7511051B2 (en) | Cidofovir peptide conjugates as prodrugs | |
US9427447B2 (en) | Anti-viral pyrimidine nucleoside derivatives | |
CA3007065C (en) | Salts of conjugates for cancer therapy | |
ITMI951450A1 (en) | ACYL ESTERS OF GANGICLOVIR ACHIRAL AMINO ACIDS AND RELATED DERIVATIVES | |
Balzarini et al. | Improvements in or relating to compositions for the treatment or prophylaxis of viral infections | |
US20090270618A1 (en) | Phosphonyl ester conjugates as prodrugs | |
CN114846051A (en) | Synthetic methods and intermediates | |
US6838547B2 (en) | Glutathiaone conjugates with distamycin derivatives having antitumoral activity | |
US20100056466A1 (en) | 2'-Cyanopyrimidine Nucleoside Compound | |
JP2003219874A (en) | Method for using peptide nucleic acid selectively binding to rna as antisense oligonucleotide, and method for producing the peptide nucleic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CONSEJO SUPERIOR DE INVESTIGACIONES CEINTIFICAS, S Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BALZARINI, JAN;CAMARASA, MARIA JOSE;VELAZQUEZ, SONSOLES;SIGNING DATES FROM 20131107 TO 20131125;REEL/FRAME:034249/0829 Owner name: KATHOLIEKE UNIVERSITEIT LEUVEN, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BALZARINI, JAN;CAMARASA, MARIA JOSE;VELAZQUEZ, SONSOLES;SIGNING DATES FROM 20131107 TO 20131125;REEL/FRAME:034249/0829 |
|
AS | Assignment |
Owner name: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, S Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BALZARINI, JAN;CAMARASA, MARIA JOSE;VELAZQUEZ, SONSOLES;SIGNING DATES FROM 20150112 TO 20150121;REEL/FRAME:034833/0033 Owner name: KATHOLIEKE UNIVERSITEIT LEUVEN, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BALZARINI, JAN;CAMARASA, MARIA JOSE;VELAZQUEZ, SONSOLES;SIGNING DATES FROM 20150112 TO 20150121;REEL/FRAME:034833/0033 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |